This content is machine translated Non-Hodgkin's Lymphoma Pomalidomide in high-risk patients. Because data on the efficacy of pomalidomide in high-risk relapsed/refractory multiple myeloma populations are sparse, a phase II study set out to evaluate the agent in patients with GEP70 or…
View Post 3 min This content is machine translated Newly diagnosed multiple myeloma Does a proteasome inhibitor offer new therapeutic options? One study discussed at the ASH meeting involved a regimen consisting of oral MLN9708 administered twice weekly plus lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma. It concludes…
